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Oral Presentations 25lower after allogeneic HSCT. Consequently, progression-free sur-
vival rates are similar in both transplant groups.
Autologous AllogeneicOutcome Probability (95% Confidence Interval)Burkitt N 5 33 N 5 45
TRM @ 100-days 9% (2–21) 11% (4–22)
Relapse @ 5-years 54% (35–73) 47% (31–63)
PFS @ 5-years 37% (21–55) 35% (22–50)
DLBCL N 5 48 N 5 18
TRM @ 100-days 8% (2–18) 11% (1–29)
Relapse @ 5-years 28% (16–42) 33% (14–56)
PFS @ 5-years 55% (40–69) 44% (23–67)
Lymphoblastic N 5 23 N 5 40
TRM @ 100-days 9% (1–23) 25% (13–39)
Relapse @ 5-years 58% (34–81) 15% (6–28)
PFS @ 5-years 33% (15–55) 50% (35–65)
ALCL N 5 27 N 5 15
TRM @ 100-days 4% (0–14) 21% (5–43)
Relapse @ 5-years 45% (25–65) 15% (2–38)
PFS @ 5-years 43% (24–63) 55% (28–80)61
MULTI-INSTITUTIONAL PHASE II STUDY OF PENTOSTATIN FOR THE
TREATMENT OF REFRACTORY CHRONIC GVHD (cGVHD) IN CHILDREN:
A PEDIATRIC BLOOD AND MARROW TRANSPLANT CONSORTIUM
(PBMTC) STUDY
Jacobsohn, D.A.1, Browning, B.1, Gilman, A.2, Lehmann, L.3,
Nemecek, E.4, Thormann,K.1, Vogelsang,G.B.5. 1Northwestern Univer-
sity/Children’s Memorial Hospital, Chicago, IL; 2UNC School of Medi-
cine, Chapel Hill, NC; 3Dana Farber Cancer Institute, Boston, MA;
4Oregon Health & Science University, Portland, OR; 5The Sidney Kim-
mel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Pentostatin, an irreversible adenosine deaminase inhibitor, was
shown in a phase II study to be effective for steroid-refractory
cGVHD. Our goal was to determine efficacy and toxicity of pentos-
tatin for steroid-refractory cGVHD in children.
Eligible patients were\ 21 years, with refractory cGVHD, hav-
ing failed#2 prior regimens. Subjects were to get 4 mg/m2 pentos-
tatin IV every 2 weeks for at least 6months. If subjects had complete
response(CR) at 6 months, pentostatin was stopped; with partial re-
sponse(PR, improvement in $1 site without progression in other)
or stable disease, treatment continued for 12months.With progres-
sion, pentostatin was discontinued. Tapering of corticosteroids be-
gan 8–12 weeks after starting study; other immunosuppression was
tapered after 3 months. Change in GVHD status was assessed every
3 months for each involved organ(skin, oral, eyes, liver, joint, GI,
pulmonary). Grades were 0(not involved), 1(mild), 2(moderate),
and 3(severe), with subject’s last available evaluation used to deter-
mine response.
A total of 51 subjects were enrolled in 26 sites; 43 are reported(41
completed therapy/off-study; 2 on-study but . 6 months therapy).
8 are too early to evaluate. Median age was 9.5 years(0.9–20.7).
GVHDgrade wasmoderate in 17, severe in 26.Most were receiving
corticosteroids at time of study entry(40); other immunosuppres-
sion was: MMF(23), FK-506(23), CSA(11) and other(5).
Subjects received a median of 12 pentostatin doses(range 1–26)
over a median of 6 months(0.5–12). Overall response rate was
44%(28% PR, 16% CR). 2 subjects had stable disease and 9 went
off-study before the 3-month evaluation(7 progression, 2 toxicity).
The table shows response by system in the 34 subjects that com-
pleted the 3 month evaluation. Skin and oral had the most notable
response. By study completion, 8 subjects were off corticosteroids,
and 20 were on\ 0.5 mg/kg/day. Most common severe adverse
events were infection(11 documented[bacterial 5 8, fungal5 1, vi-
ral 5 2]). Ten subjects were removed due to toxicity and 2 due to
cancer relapse; 6 had had a response to pentostatin. Four deaths oc-
curred either on-study or within 28 days after last dose from infec-
tion(3), leukoencephalopathy(1).Pentostatin has activity in the treatment of refractory cGVHD in
children, with acceptable toxicity. Skin and oral cGVHD has the
most benefit. Adding pentostatin allows significant tapering of cor-
ticosteroids. Further follow-up is needed to evaluate durability of
response.Response by System in the 34 Subjects on Study at least through 3-month
Evaluation
Total StableSystem Manifestations N Response Progression DiseaseSkin Rash/Lichenoid 29 17 9 3Fasciitis/
Sclerosis21 15 3 3Oral symptoms/
lichenoid and/or
erythema19 15 2 2Ocular symptoms/need
for treatment16 7 5 4Joints Arthralgias/
Contractures16 6 6 4Gastrointestinal Vomiting/
Abdominal Pain/
Diarrhea15 7 6 2Liver Total Bilirubin 3 0 2 162
HIGH RESOLUTION HLA TYPING AND ATG PREVENT CHILDREN WITH
ALL FROM GVHD AND TREATMENT RELATED MORTALITY AFTER UNRE-
LATED DONOR STEM CELL TRANSPLANTATION
Peters, C.1, Schrauder, A.2, Schrappe, M.2, Stackelberg, A.3,
Zimmermann, M.4, Klingebiel, T.5, Handgretinger, R.6, Holter, W.7,
Poetschger, U.8, Gadner, H.1. 1St. Anna Children’s Hospital, Vienna,
Austria; 2University Hospital Schleswig-Holstein, Kiel, Germany; 3Uni-
versity Hospital, Hannover, Germany; 4Charite, University Medicine,
Berlin, Germany; 5University Hospital, Frankfurt, Germany; 6Univer-
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Graft versusHostDisease (GVHD) is still one of themost impor-
tant risk factor for mortality and long term morbidity in children
and adolescents undergoing allogeneic stem cell transplantation
(SCT) from unrelated donors (UD). In 2003 the Berlin-Frank-
furt-Muenster (BFM)-Study Group initiated a prospective, interna-
tional, multicenter trial on allogeneic SCT in children with high-
risk ALL (ALL-SCT-BFM 2003). In this ongoing trial main goals
are the standardisation and harmonisation of the SCT procedure
and the question, if SCT from a HLA-genoidentical sibling donor
(MSD) is equivalent to SCT from a matched donor (MD). A MD
was defined as related or donor with 10/10 or 9/10 HLA matches,
determined by HLA high-resolution typing (4 digits/allel: A, B,
C, DRB1 and DQB1). Between September 2003 and June 2007,
381 patients (185 in CR1, 196 in CR2 or after subsequent relapse)
were recruited by 27 participating SCT centers in Austria, Germany
and Switzerland. Indications for SCT were poor response to induc-
tion treatment, cytogenetic aberrations, early bone marrow relapse,
or any subsequent ALL relapse. GVHD-prophylaxis for patients
undergoing MSD-SCT consisted of only CSA to augment the
GVL-effect. Patients transplanted from MD received CSA, short
MTX and rabbit ATG. The recommended conditioning regimens
were TBI1VP16 for patients . 2 years; in children younger than
2 years, TBI was substituted by busulfan and cyclophosphamide.
Unmanipulated bone marrow was used in 73% of MSD- and
MD-SCT as recommended by the protocol. No significant differ-
ence in the occurrence of acute and chronic GVHD was observed:
after MSD-SCT: 20% of patients did not develop any aGVHD,
37% had grade I, 31% grade II, 4% grade III and 4% grade IV. Af-
ter MD-SCT, 26% had no GVHD, 39% grade I, 27% grade II, 5%
grade III and 3% grade IV. Limited cGVHD was observed in 7%
vs. 8% and extensive cGVHD in 16% vs. 5% after MSD and MD
26 Oral PresentationsSCT, respectively. A trend for more severe aGVHD and extensive
cGVHD was observed in patients who received peripheral blood
SC from MSD. One year-treatment-related mortality is still low
(7%) in both groups and reflects the high performance quality of
the participating centers. We conclude that allogeneic SCT from
matched donors identified by high resolution typing provides an ex-
cellent chance to rescue children and adolescents with high risk
ALL. The combination of CSA, short MTX and ATG prevents
acute and chronic GVHD without jeopardising the GVL effect.63
OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN 159 YOUNG PATIENTS WITH PEROXISOMAL AND LYSOSOMAL
STORAGE DISORDERS AT A SINGLE CENTER
Prasad, V.K.1, Mendizabal, A.2, Parikh, S.H.1, Szabolcs, P.1,
Driscoll, T.1, Page, K.1, Lakshinarayanan, S.1, Allison, J.1, Wood, S.1,
Semmel, D.1, Escolar, M.L.3, Martin, P.L.1, Carter, S.2,
Kurtzberg, J.1. 1Duke University Medical Center, Durham, NC; 2The
EMMES Corporation, Rockville, MD; 3University of North Carolina,
Chapel Hill, NC.
Background: Bone marrow transplantation benefits patients
with lysosomal and peroxisomal storage diseases (LSD). Umbilical
cord blood (UCB) may be potential graft source for many patients
lacking suitable adult donors. We present the outcomes of Unre-
latedUCB transplantation (UCBT) in a large series of LSDpatients
from a single center. Methods: Using myeloablative conditioning
with busulfan1cyclophosphamide1antithymocyte globulin and
graft-versus-host disease (GvHD) prophylaxis with Cyclospori-
ne1methylprednisolone(n 5 125) or cyclosporine1cellcept (n 5
34), 159 consecutive LSD patients with Hurler, Krabbe, Sanfilippo,
Metachromatic Leukodystrophy, Adrenoleukodystrophy, Hunter,
and other diagnoses received UCBT at Duke in 1995–2007. CBU
from 8 US public banks were screened and those with high-normal
enzyme utilized. Organ function and disease specific studies were
performed pre- and post-UCBT. KM estimates of engraftment,
survival and GvHD probabilities were calculated and multivariate
models were analyzed for a variety of graft and patient factors.
Results: Sixty-two (39%) were girls; 16.3% minorities; 19.5%
CMV seropositive, and 41.5% had a Lansky\ 80%. Age was 1.5
yrs(range 0.05–26.3). Majority of grafts were 5/6(47%) or 4/
6(46%) by intermediate-res HLA-A and -B and high-res HLA-
DRB1. The median(range) cell dose/kg of TNC(pre-cryo),
TNC(infused), CD34(infused) and CFU(post-thaw) was 9.7 
107(2.2–50.4), 7.6  107(1.5–32.4), 2.1  105(0.4–104.8) and 5.7
 104(0.0–105.3), respectively. The cumulative incidence neutro-
phil and platelet engraftment was 87.1% (95%CI 82%-92%) and
71.0% (95%CI 64%-78%) in a median of 22 and 87 days, respec-
tively. The probability of Grade III/IV acute GvHD was
10.3%(95%CI 5%-15%) by day100. Chronic GvHD developed
in 26(13–limited). Overall Survival(OS) at 1, 3, and 5 years was
71.8%(95%CI 65%-79%), 62.7%(95%CI 55%-71%) and
58.2%(95%CI 50%-67%), respectively. In multivariate analysis,
Lansky 80–100(p \ 0.0001), CFU infused .5.7  104/kg (p 5
0.02), and matched ethnicity(p 5 0.05) increased OS. Once en-
grafted, all but 3 maintained chimerism.90% and all but 4 normal-
ized enzymes. In high performance status(Lansky 80–100) patients,
theOS at 1, 3 and 5 yearswas 88.4%, 83.5%, and 79.5%, respectively.
Conclusions: Unrelated Cord blood is an excellent graft source
for treatment of LSD patients, particularly when transplantation is
performed in early stages. Pre-transplant performance status and
post-thaw CFU dosing were highly predictive of overall survival.64
LUNG BIOPSY (BX) HAS A SIGNIFICANTLY HIGHER DIAGNOSTIC YIELD
COMPARED TO BRONCHOALVEOLAR LAVAGE (BAL) IN PEDIATRIC HE-
MATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS
Cooney-Qualter, E., Satwani, P., van de Ven, C., Baldinger, L., Bye, M.,
Bhatia, M., Garvin, J., George, D., Bradley, M.B., Schwartz, J.,
Wolownik, K., Foley, S., Hawks, R., Kohl, V., Cairo,M.S.Morgan Stan-ley Children’s Hospital of NewYork-Presbyterian, Columbia University,
New York, NY.
Pulmonary complications (PC) following HSCT remain a signif-
icant source of morbidity and mortality in both the early and late
HSCT period. BAL has been a useful initial diagnostic tool in the
evaluation of post HSCT PC; however, the sensitivity of BAL ver-
sus Lung Bx in pediatric HSCT pts has not been analyzed. We re-
viewed 208 pediatric HSCT recipients who underwent a total of
252 HSCT. Allo (174) Myeloablative Conditioning (MAC)
(54%), Reduced Intensity Conditioning (RIC) (45%)and Auto
(78) All MAC. Sixty-six patients (32%) underwent 107 BAL for fe-
ver, respiratory distress, and/or pulmonary infiltrate(s) on chest X-
ray/CT scan: M:F 5 38:28, median age 10 yrs (.33–21), mean # of
BAL/pt 2 (1–8). The probability of requiring BAL after HSCT in
all pts was 23.7% (CI95:18–29.4); RIC 21% (11.5–30.6) vs MAC
24% (16.8–31.6) p 5 0.61 (NS). The median day s/p Auto and
Allo at the time of BAL was Day 131 and 194, respectively. The
probability of AGVHD Grade II-IV at the time of BAL after Allo
SCT was 70% (50–90) and cGVHD was 85% (57–100). The risk
of having cGVHD was significantly higher in the BAL vs no BAL
group (p\0.001). Pathogenswere identified in 37 BAL (35%): Bac-
teria (16), Fungus (12), Viral (13). Seventeen of the 208 pts (8%) un-
derwent a total of 21 lung biopsies. Nineteen (90%) of the biopsies
identified at least one etiology: Infection (12), Fibrosis (4), GVHD
(5), recurrent malignant disease (1). Of the 9 biopsies that were per-
formed within 30 days of an inconclusive BAL (median 13 days s/p
BAL), 6 (67%) identified at least one infection pathogen: Aspergil-
lus (1), CMV (1), Parainfluenza/Influenza (1), Parainfluenza 3 (1),
MAC (1), HSV-1 (1). There were no Grade III/IV toxicity second-
ary to BAL or Bx. Lung autopsies were performed in thirteen pts
(20%) whom underwent a negative BAL. Five (38%) provided at
least one pathogen previously unidentified via BAL performed
within 30 days: Staph Epi (1), Adenovirus (2), CMV (2), Candida
Glabrata (1). The overall survival (OS) in pts whom required BAL
and lung Bx was 45% (16–75) vs 76% (69–83%, p\ 0.003) in the
no BAL and no Bx group This data suggest that a BAL post
HSCT in pediatric recipients will likely only yield a Diagnosis
(Dx) 35% of the time compared to lung Bx which had a 90% diag-
nostic yield. In the future a paradigm will be required to determine
which pediatric HSCT recipients may benefit by having an initial
lung Bx and foregoing an initial BAL to Dx PC.65
INCIDENCE, PREDISPOSING FACTORS AND OUTCOME OF ENGRAFT-
MENT SYNDROME IN PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT
RECIPIENTS
Albert, M.H.1, Stachel, D.2, Schmid, I.1. 1Dr. von Haunersches Kinder-
spital der LMU, Munich, Germany; 2Kinderklinik der Universita¨t Er-
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Background: Engraftment syndrome (ES) has been recognized
as an inflammatory condition during neutrophil recovery after he-
matopoietic stem cell transplantation (HSCT) characterized by
non-infectious fever and skin rash. It has been reported to occur fre-
quently after autologous HSCT in children and adults and has been
shown to be an independent risk factor for increased transplant re-
lated mortality. However virtually no data exist on its occurrence
after allogeneic HSCT in children. Methods: To determine inci-
dence, predisposing factors for and complications of ES in a pediat-
ric transplant cohort, we analyzed 61 consecutive recipients of
a myeloablative allogeneic HSCT for the occurrence of ES. Diag-
nosis of ES was established when children presented with $2 of
the following symptoms within 7 days before engraftment: (1) fever
of unknown origin.38.0C, (2) erythematous skin rash, (3) weight
gain $5% and albumin drop # 90% of pretransplant levels or (4)
dyspnea, hypoxia or pulmonary infiltrates. Results: Incidence of
ES in this cohort was 48% (29/61). Post transplant G-CSF admin-
istration (p5 0.03) and a higher number of total nucleated cells (p5
0.02) were significant risk factors predisposing for the development
of ES. Other previously reported factors such as source of stem cells
(BM vs. PB; p5 0.88), underlying disease (malignant vs. non malig-
nant; p 5 0.18), early neutrophil recovery (p 5 0.16) and
